Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role
Φόρτωση...
Ημερομηνία
Συγγραφείς
Pelidou, S. H.
Zou, L. P.
Deretzi, G.
Oniding, C.
Mix, E.
Zhu, J.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Exp Neurol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Experimental autoimmune neuritis (EAN) is a CD4(+) T-cell-mediated demyelinating disease of the peripheral nervous system (PNS). We examined the effect of recombinant mouse interleukin 17 (rmIL-17) on chronic EAN induced in Lewis rats by inoculation of P2 57-81 peptide in Freund's complete adjuvant. Animals were treated nasally for 6 days with either 0.1 or 0.9 microg/rat/day rmIL-17 from the onset of neurological signs, i.e., days 9 to 14 postimmunization (p.i.). Prolonged follow-up demonstrated a chronic course in control and rmIL-17-treated rats. Treated rats had more severe disease initially (days 18-36 p.i.) with a stronger enhancing effect observed with the higher rmIL-17 dose. At day 19 rmIL-17-treated rats showed increased infiltration of inflammatory cells into the sciatic nerve, more severe demyelination, augmented proliferation of regional lymph node cells, and increased serum levels of tumor necrosis factor-alpha. After the initial phase of disease enhancement the IL-17-treated EAN rats improved gradually and ultimately recovered completely, whereas the control EAN rats remained affected until the end of the observation (day 120 p.i.). The lower dose of rmIL-17 induced an earlier recovery from clinical deficits than the higher one. The results indicate that IL-17 plays an immunoregulatory role in chronic EAN which could have implications for immunomodulatory treatments of chronic autoimmune disease of the PNS.
Περιγραφή
Λέξεις-κλειδιά
Acute Disease, Administration, Intranasal, Animals, Cells, Cultured, Chronic Disease, Disease Progression, Dose-Response Relationship, Drug, Immunohistochemistry, Interleukin-17/administration & dosage/*immunology, Leukocytes, Mononuclear/cytology/drug effects, Lymphocyte Activation/drug effects/immunology, Male, Mice, Myelin P2 Protein/immunology, Neuritis, Autoimmune, Experimental/*immunology/pathology, Peptide Fragments/immunology, Rats, Rats, Inbred Lew, Recombinant Proteins/administration & dosage/immunology/therapeutic use, Sciatic Nerve/drug effects/pathology, Tumor Necrosis Factor-alpha/metabolism
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/10785455
http://ac.els-cdn.com/S0014488600973576/1-s2.0-S0014488600973576-main.pdf?_tid=bcff35d1260c14239710b3ce2f6f4eec&acdnat=1332844618_80dd581d1d066ba347bdc6937731c840
http://ac.els-cdn.com/S0014488600973576/1-s2.0-S0014488600973576-main.pdf?_tid=bcff35d1260c14239710b3ce2f6f4eec&acdnat=1332844618_80dd581d1d066ba347bdc6937731c840
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής